DEEP TECH PLATFORM COMPANY · AMTZ, VISAKHAPATNAM
Compounding Deep-Tech Platforms into First-in-Class Bio-Solutions.
"We build platforms, not products." By converging marine biotechnology, catechol chemistry, and advanced nanomaterials into scalable clinical engines, Akrivis turns complex biological insights into market-ready therapeutics — manufactured at giga-scale at AMTZ.
"We build platforms, not products. Each product is the expression of a platform; each platform is a body of knowledge that compounds."
Institutional-Grade Validation at Every Layer
By anchoring operations inside Asia's premier MedTech ecosystem and maintaining active regulatory clearances across CDSCO, US FDA, and European standards, Akrivis eliminates buyer skepticism at the point of first contact.
Regulatory Suite: CDSCO Licensed // US FDA Registered Facility Status // ISO Certified. Active seat on BIS MHD-20 — drafting national standards for advanced medical devices, aligning Indian innovation with EN ISO 13485 and European MDR.
IP Matrix: 8 Filed Patents // 23+ Validated Commercial Products across therapeutic, device, and cosmeceutical portfolios.
THE FOUNDER MATRIX
The Clinical-Cellular Convergence
By uniting a veteran Surgeon-Scientist who understands real-world surgical trauma with a Cancer Biologist who commands ultra-rigorous cellular mechanics, Akrivis achieves a convergence that transforms biological complexity into scalable, first-in-class bio-solutions.
Macro-Application
Surgeon-Scientist: Engineering out the limitations of invasive surgery
Dr. Sarat Babu Janipalli brings 20+ years of clinical architecture and surgical reality. By identifying unmet surgical needs at the point of care, he drives the development of non-invasive alternatives — the force behind TympanoSeal™.
20+ years clinical surgery · Founder & CEO · Platform architect · IP strategist
Micro-Mechanism
Cancer Biologist & Molecular Scientist: Commanding cellular precision
Dr. Vamshi Krishna Irlapati commands the ultra-rigorous cellular mechanics of oncology. Because he masters molecular pathways at the deepest level, Akrivis's regenerative tissue platforms possess unmatched biological precision — the science behind SynExo™.
PhD Biotechnology · Co-Founder & CSO · Pre-clinical validation · Molecular logic
The Convergence
Clinical need meets cellular solution at manufacturing scale
By converging macro-application insight with micro-mechanism mastery, Akrivis accelerates from laboratory discovery to cGMP manufacturing — thereby ensuring every platform delivers both clinical efficacy and commercial scalability.
5+ active platforms · 8 filed patents · 23+ commercial products · cGMP at AMTZ
Five Platforms. One Compounding Engine.
By converging marine biotechnology, catechol chemistry, and advanced nanomaterials into a unified platform architecture, Akrivis accelerates each discovery from laboratory insight to validated commercial product — thereby ensuring every platform compounds into the next.
TympanoSeal™ NeoTympanum
Non-Invasive Tympanic Membrane Repair
A novel medical device for non-invasive tympanic membrane repair. Designed as a fifteen-minute in-clinic procedure, offering a non-surgical alternative to conventional tympanoplasty. Chronic suppurative otitis media affects approximately 65–330 million people globally (WHO, 2004), with a disproportionate burden in South and Southeast Asia.
- First-in-class to our knowledge
- Non-invasive in-clinic procedure
- Scalable manufacturing
- Large addressable patient population
SynExo™ Therapeutics
Regenerative Therapeutics Platform
The core therapeutic platform spanning wound care, burn care, and regenerative medicine. Manufactured under cGMP at the AMTZ facility in Visakhapatnam.
- Multi-source platform architecture
- cGMP manufacturing at AMTZ
- Accelerated regulatory pathway
- Broadest platform of its kind in India
EXOGLAM
Advanced Cosmeceutical Portfolio
Therapeutic and cosmetic formulations for aesthetic medicine, wound repair, and adjacent regenerative indications. European market access strategy supports international expansion.
- Dual-track: cosmeceutical + therapeutic
- European market access established
- Licensed to international partners
- Expanding global distribution
HEMOSOME OxyRescue Serum
In Partnership with Hemarina SA, France
Commercialisation of oxygenation technology developed by Hemarina SA of France. Topical applications in wound healing and aesthetic medicine.
- Exclusive partnership with Hemarina SA, France
- Unique biological mechanism
- Wound healing + aesthetic medicine
- International technology partnership
ClearSight Nano · Nano Collagen · VOC · MPTR
Nanomaterials, Diagnostics & Emerging Technologies
A portfolio of emerging platforms spanning nanomaterials, collagen technologies, non-invasive diagnostics, and next-generation therapeutic delivery systems.
- Exclusive supply agreement with Holista Colltech (ASX: HCT)
- Non-invasive diagnostic platform
- Next-generation delivery systems
- Optical nanomaterials
The Dual-Track Grid
By separating high-stakes clinical innovation from scaled commercial delivery, Akrivis ensures each track receives the precise regulatory, manufacturing, and distribution architecture it demands.
Audience: Global Cosmetic, Wellness, & B2B Distributors. Active international consumer footprints including Harrods UK, SkinSeqnc Canada, and Southeast Asian markets. Kinetic absorption, cGMP delivery capacity, and premium positioning.
EXOGLAM Serums
Aesthetic Medicine
Approved
Nano Collagen Range
Dermal Care
Holista Colltech Partnership
HEMOSOME OxyRescue
Topical Oxygenation
Hemarina SA Partnership
SynExo™ Hair Growth
Trichology
Approved
SynExo™ Anti-Ageing
Cosmeceutical
Approved
Quantitative Proof & Enterprise Tools
By leveraging exclusive cross-border biotechnology alliances with global innovators like Holista Colltech Ltd, Akrivis delivers verified quantitative advantages that transform static data into enterprise lead-generation engines.
The Kinetic Absorption Advantage
Verified 84x Bio-Availability Multiplier
Holista Colltech Alliance: By leveraging exclusive cross-border biotechnology alliances with global innovators like Holista Colltech Ltd (ASX: HCT), Akrivis delivers a verified 84x bio-availability multiplier over standard molecular weights — transforming collagen delivery from passive topical application into active dermal penetration.
Exclusive supply agreement with ASX-listed Holista Colltech Ltd (ASX: HCT) — delivering a verified 84x bio-availability multiplier over standard molecular weights.
Yield Estimator
SynExo™ Production Calculator
Giga-scale production: Illustrative estimates based on Akrivis manufacturing facility at AMTZ, Visakhapatnam. Actual yields vary based on production parameters. Contact us for validated production data.
The Team
A multidisciplinary leadership team architecting the convergence of clinical surgery, molecular biology, regulatory strategy, and global commercial scale.
Dr. Sarat Babu Janipalli
Founder & CEO
A veteran Surgeon-Scientist who understands application, real-world surgical trauma, and patient needs. By engineering out the limitations of traditional invasive operations, Dr. Sarat drives the development of first-in-class non-invasive alternatives — the clinical force behind TympanoSeal™. Leads platform architecture, IP strategy, and regulatory navigation.
Dr. Vamshi Krishna Irlapati
Co-Founder & Chief Scientific Officer
A powerhouse Cancer Biologist & Molecular Scientist who commands cellular pathways, tissue engineering, and molecular logic. Because he masters the ultra-rigorous cellular mechanics of oncology, Akrivis’s regenerative tissue platforms like SynExo™ possess unmatched biological precision. Translates research into reproducible manufacturing protocols.
Mr. Ravi Eswarapu
Co-Founder & Chief Business Officer
Drives commercial strategy, international partnerships, and investor relations. Architect of the B2B distribution network spanning India, Europe, and the Middle East.
CA (Dr.) Mahaveer Chaplot
Founder — Private Equity & Strategic Finance
Prominent Chartered Accountant, educator, and community leader with over two decades of expertise in private equity, banking, and agripreneurship. Director of Agribid, an AI-driven platform empowering farmers. General Secretary of the Certified Accountants Division, International Council of Jurists. Currently serving as Sachiv (Secretary) for JITO Apex (2024–26).
Mr. Sampath Kumar Janipalli
Founder — International Operations
Manages international operations, entity coordination, and cross-border supply chain logistics. Anchors European distribution and partnership infrastructure.
Mr. Abhijit Samant
Director — Regulatory Affairs & Quality Systems
Oversees CDSCO submissions, ISO compliance, and quality management systems across the AMTZ manufacturing facility. Navigates accelerated regulatory pathways for therapeutic approvals.
Mr. Kuldeep Singh
Director — Manufacturing & Supply Chain
Leads manufacturing operations at the AMTZ facility, supply chain optimisation, and production scaling. Maintains cGMP compliance and quality standards across the commercial portfolio.
Certifications & Standards
Regulatory compliance and quality management systems underpinning every product in the portfolio.
CDSCO
Central Drugs Standard Control Organisation
Manufacturing licence for cosmeceutical and therapeutic formulations. Full commercial portfolio approved.
ISO 22716:2007
Cosmetics GMP
Good Manufacturing Practice for cosmetic products. Covers the AMTZ facility production lines for the entire cosmeceutical portfolio.
ISO 9001:2015
Quality Management Systems
Organisation-wide quality management system certification covering design, development, manufacturing, and distribution of cosmeceutical and therapeutic products.
US FDA
United States Food & Drug Administration
Facility registration and product listing for export-grade cosmeceutical formulations. Enables direct export through registered distribution channels.
BIS MHD-20
Bureau of Indian Standards — Medical & Healthcare Devices
Institutional membership on the Bureau of Indian Standards MHD-20 committee — the Indian equivalent of a CEN/CENELEC or ISO technical committee for medical devices. Akrivis participates in drafting national standards for medical and healthcare devices, analogous to how European companies contribute to EN ISO 13485 or MDR harmonised standards.
TÜV Rheinland
Independent Elemental Validation
Independent third-party validation of platform materials. Confirms elemental composition and purity across the commercial portfolio.
Manufacturing Anchor: AMTZ, Visakhapatnam
The Andhra Pradesh MedTech Zone (AMTZ) is Asia's first integrated medical device manufacturing ecosystem. Akrivis operates its cGMP facility within AMTZ, providing access to shared infrastructure, regulatory support, and a cluster of complementary medical device manufacturers.
Strategic Partnerships
A curated network of technology providers, distribution partners, and institutional supporters enabling global reach from our AMTZ manufacturing base.
Technology Partners
Hemarina SA
Morlaix, France
French marine biotechnology company specialising in oxygen-carrying molecules derived from Arenicola marina. Hemarina's M101 molecule forms the basis of the HEMOSOME OxyRescue platform — a topical oxygenation technology with applications in wound healing and aesthetic medicine.
Exclusive India commercialisation rights
Holista Colltech Ltd
Kuala Lumpur, Malaysia (ASX: HCT)
ASX-listed biotechnology company specialising in nano-scale collagen extraction from ovine sources. Holista's proprietary process achieves 84× greater dermal absorption than standard collagen — forming the basis of Akrivis's Nano Collagen platform.
Exclusive supply agreement
Distribution Partners
Elegantes London / Harrods UK
United Kingdom
Premium distribution channel for the EXOGLAM cosmeceutical range through Harrods and affiliated luxury retail networks in the United Kingdom.
Distribution PartnerSkinSeqnc
Canada
Canadian distribution partner for the SynExo™ and EXOGLAM cosmeceutical portfolios. Covers the North American premium skincare market.
Distribution PartnerNano-Malaysia
Malaysia
Strategic partner for nano-collagen and cosmeceutical distribution across the Southeast Asian market.
PartnerDefine Bio
India
Subsidiary focused on domestic Indian market distribution and brand development for the cosmeceutical portfolio.
SubsidiaryIncubation & Acceleration Partners
AMTZ — Andhra Pradesh MedTech Zone
Manufacturing HubAsia's first integrated medical device manufacturing ecosystem. Akrivis operates its cGMP facility within AMTZ, providing access to shared infrastructure, regulatory support, and a cluster of complementary medical device manufacturers.
Nadupuru, Anakapalli District, Visakhapatnam, Andhra Pradesh 531019
RTIH — Ratan Tata Innovation Hub
Corporate OfficeInnovation hub providing incubation support, mentorship, and access to the broader Tata ecosystem for deep-tech startups.
IIT Hyderabad Campus, Kandi, Sangareddy, Telangana 502285
High-Intent Engagement Pathways
By routing each inbound inquiry through a purpose-built segmentation layer, Akrivis ensures every stakeholder receives precisely the information, access, and response architecture they require.
IP Portfolio
Send a High-Intent Inquiry
Route your inquiry directly to the Akrivis leadership team. Each submission is triaged by intent and responded to within 2 business days.